About VUR from OP ghai and nelson paediatric and recent guidelines update based on INICET and NEETPG syllabus
Reading File
Finding Sources
Finding Sources
Searching PubMed
"vesicoureteral reflux"[MeSH Terms] AND management
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
"vesicoureteral reflux"[MeSH Terms] AND guidelines
Finding Sources
Reading File
Searching PubMed
"vesicoureteral reflux"[MeSH Terms] AND "urinary tract infection"[MeSH Terms]
Finding Sources
Searching the Web
VUR vesicoureteral reflux OP Ghai Nelson pediatrics INICET NEETPG grading treatment guidelines 2024
Searching PubMed
vesicoureteral reflux children management
Reading Article
Reading Article
Reading Web Page
VUR grading classification diagnosis treatment management children
Reading File
Searching the Web
EAU ESPU 2024 vesicoureteral reflux guidelines update children recommendations
Excellent - I now have comprehensive material. Let me compile the full, detailed answer for INICET/NEETPG based on OP Ghai, Nelson's, and current guidelines.
Vesicoureteral Reflux (VUR) - Comprehensive Review
For INICET / NEETPG | Based on OP Ghai, Nelson's Pediatrics & 2023-24 Guidelines
1. Definition
Vesicoureteral reflux (VUR) is the abnormal retrograde flow of urine from the urinary bladder into the ureter(s) and/or renal pelvis during bladder filling or voiding. It is one of the most common urological anomalies in infants and children.
2. Types
| Type | Description |
|---|---|
| Primary VUR | Congenital anomaly - short intramural (submucosal) segment of ureter within the bladder wall; inadequate flap-valve mechanism |
| Secondary VUR | Due to elevated intravesical pressure (posterior urethral valves, neurogenic bladder, bladder bowel dysfunction - BBD) |
Key concept (Ghai/Nelson): The normal intravesical ureter length:diameter ratio is 5:1. A short submucosal tunnel is the principal defect in primary VUR.
3. Epidemiology
- Incidence: ~1% in general pediatric population; ~30-40% of children investigated for UTI
- More common in females (female:male = 4:1 after infancy; males detected more often prenatally)
- Whites > Blacks (racial predilection)
- Familial tendency: Sibling risk ~30%; offspring risk ~66% (autosomal dominant with variable penetrance)
- Spontaneous resolution in ~80% of low-grade VUR by puberty
4. International Classification / Grading (VCUG-based)
The International Reflux Study Committee (IRSC) grading is standard:
| Grade | Description | Key Feature |
|---|---|---|
| I | Reflux into ureter only; no dilatation | Ureter not dilated |
| II | Reflux into renal pelvis/calyces; no dilatation | No dilatation of ureter/pelvis |
| III | Mild/moderate dilatation of ureter and pelvis; minimal blunting of calyces | Mild dilatation |
| IV | Moderate dilatation of ureter and pelvis; blunting of calyces; papillary impressions still visible | Moderate dilatation |
| V | Gross dilatation and tortuosity of ureter; papillary impressions absent; intrarenal reflux | Severe; intrarenal reflux |
High-grade VUR = Grades III-V (dilating VUR)
Low-grade VUR = Grades I-II
NEETPG pearl: Grade V is associated with intrarenal reflux and carries the highest risk of renal scarring.
5. Pathophysiology of Renal Injury
VUR + UTI = Reflux Nephropathy (previously called "chronic atrophic pyelonephritis")
- Ascending bacteria reach renal parenchyma via intrarenal reflux
- Inflammatory response → focal renal scars (polar distribution, as compound papillae at poles allow intrarenal reflux)
- Scars → loss of functioning nephrons → compensatory hypertrophy → hypertension → CKD
- Compound papillae (at upper and lower poles) are more susceptible to intrarenal reflux
- Simple papillae (middle calyces) resist intrarenal reflux
Consequences of reflux nephropathy:
- Hypertension (15-30% of affected children)
- Proteinuria (marker of progressive injury)
- CKD / ESRD (5-10% of pediatric ESRD cases)
- Toxemia of pregnancy (in females with unrecognized reflux nephropathy)
- Growth failure
6. Clinical Presentation
Presentation varies by age:
| Age Group | Typical Presentation |
|---|---|
| Neonates/Infants | Antenatal hydronephrosis, septicemia, failure to thrive |
| Older infants/toddlers | Febrile UTI (pyelonephritis) - most common presentation |
| Older children | Recurrent UTI, enuresis, voiding dysfunction, hypertension |
| Incidental | Sibling screening, antenatal scan |
Key features pointing to VUR in UTI:
- Febrile UTI (especially non-E. coli) in a child < 2 years
- Recurrent UTI
- Abnormal renal ultrasound
- Family history of VUR
7. Investigations
A. Urine Culture
- Gold standard for diagnosing UTI
- Significant growth: >10^5 CFU/mL (midstream); >10^4 CFU/mL (catheter sample)
- ISPN 2024 guideline: >10^4 CFU/mL considered significant in infants when clinical suspicion is strong
B. Voiding Cystourethrogram (VCUG / MCU)
- Gold standard for diagnosing and grading VUR
- Performed after treating acute UTI (usually 4-6 weeks later)
- Also shows: posterior urethral valves, bladder trabeculation, diverticula, urethral anatomy
- Indications for VCUG/MCU (ISPN 2024):
- Recurrent UTI (2+ febrile episodes)
- Abnormal renal ultrasound
- Children <2 years with non-E. coli UTI
- First febrile UTI in boys (some guidelines)
C. Renal Ultrasound
- First-line imaging; non-invasive
- Detects hydronephrosis, renal scarring (late), duplex systems
- Cannot reliably detect or grade VUR
- Normal USG does not exclude VUR
D. DMSA Radionuclide Scan
- Best for detecting acute pyelonephritis (photopenia) and renal scars (permanent photopenia)
- Acute scan: within 72 hours of febrile UTI - not routinely recommended (ISPN 2024)
- Follow-up DMSA (at 6 months post-acute infection): Indicated in children with recurrent UTI + high-grade (III-V) VUR
- Split renal function can be assessed
E. Nuclear Cystogram (Indirect/Direct)
- Less radiation than VCUG
- Better sensitivity for detecting VUR
- Cannot grade or show anatomy - used for follow-up, not initial diagnosis
- Indirect: after IV DTPA/MAG3 during voiding phase (no catheterization needed)
- Direct: requires catheterization
F. Contrast-Enhanced Voiding Urosonography (ceVUS)
- Newer technique, no radiation
- Gaining acceptance as alternative to VCUG in selected centers
8. Spontaneous Resolution Rates
| Grade | Resolution rate (overall) | Time |
|---|---|---|
| I | ~80% | 3-4 years |
| II | ~80% | 4-5 years |
| III | ~50% | 5-6 years |
| IV | <40% | Variable |
| V | ~10-20% | Rarely spontaneous |
Factors favoring spontaneous resolution:
- Lower grade
- Younger age at diagnosis
- Unilateral VUR
- Male sex (better resolution than females)
- No BBD
9. Management
A. General Principles
The three goals of management are:
- Prevent recurrent febrile UTIs
- Prevent renal injury/scarring
- Minimize treatment morbidity
BBD (Bladder Bowel Dysfunction) must be identified and treated first - it is the most important modifiable risk factor for treatment failure, breakthrough UTI, and persistent VUR.
B. Continuous Antibiotic Prophylaxis (CAP)
Drugs used for CAP:
| Drug | Dose | Notes |
|---|---|---|
| Trimethoprim-sulfamethoxazole | 1-2 mg/kg/day TMP component | Not in <2 months |
| Nitrofurantoin | 1-2 mg/kg/day | Not in <1-2 months |
| Cefalexin | 10-15 mg/kg/day | Used in neonates |
| Amoxicillin | 10 mg/kg/day | Used in neonates |
| Nalidixic acid | Not preferred now |
Administered as single bedtime dose (residual urine in bladder at night)
CAP Indications (synthesized from ISPN 2024, AUA, EAU 2023):
| Clinical Scenario | Recommendation |
|---|---|
| Age <1 year with any grade VUR + febrile UTI | CAP recommended |
| High-grade VUR (III-V) in any age | CAP recommended |
| VUR + BBD (any grade) | CAP until BBD resolves |
| Grade I-II, toilet-trained, no BBD, no UTI in 1 year | Stop prophylaxis |
| Normal urinary tract after UTI | CAP NOT indicated |
ISPN 2024 key recommendation: CAP should be stopped if the child is:
- Toilet-trained
- Free of BBD
- Breakthrough UTI-free for the last 1 year
C. EAU/ESPU 2023 Updated Guidelines (published Eur Urol 2024; PMID 38182493)
Key updates:
- BBD is critical - common in toilet-trained children with UTI ± VUR; increases risk of febrile UTI and renal scarring
- CAP is not required in every VUR patient - selective use based on risk
- CAP duration - practically, continue until BBD resolves (no set duration in evidence)
- High-grade VUR management: Initial medical treatment; surgery reserved for:
- CAP non-compliance
- Breakthrough febrile UTIs despite CAP
- Symptomatic VUR persisting at long-term follow-up
D. ISPN 2024 Guidelines (Indian Society of Pediatric Nephrology - Hari P et al., Pediatr Nephrol 2024)
(Most relevant for INICET/NEETPG)
Key recommendations:
- Urine culture >10^4 CFU/mL significant in infants with strong clinical suspicion
- Oral antibiotics can treat acute pyelonephritis in non-toxic infants (7-10 days)
- Acute-phase DMSA scan is NOT recommended routinely
- MCU indicated in: recurrent UTI, abnormal kidney USG, children <2 years with non-E. coli UTI
- DMSA scan indicated only in: recurrent UTI + high-grade (III-V) VUR
- No prophylaxis in children with normal urinary tract after UTI
- Prophylaxis recommended for: BBD + any grade VUR; high-grade VUR
- Stop prophylaxis when: toilet-trained + no BBD + no UTI in last 1 year
- Surgery for: parental preference over CAP; breakthrough febrile UTIs on prophylaxis
E. Surgical Management
Indications for surgery:
- Persistent high-grade VUR (IV-V) not resolving with time
- Breakthrough febrile UTIs despite CAP
- New/progressive renal scarring on follow-up DMSA
- Patient/parental preference
- Non-compliance with medical management
- Allergy to prophylactic antibiotics
Surgical options:
| Procedure | Method | Notes |
|---|---|---|
| Endoscopic injection (STING/HIT procedure) | Subureteral/intraureteral injection of bulking agent (Deflux - dextranomer/hyaluronic acid) | Minimally invasive; day surgery; lower success for grade V |
| Open ureteral reimplantation | Cohen (cross-trigonal), Politano-Leadbetter, Glenn-Anderson | Gold standard; ~98% success rate |
| Laparoscopic/robotic reimplantation | Minimally invasive open equivalent | Gaining popularity |
STING technique success rates:
- Grades I-III: 70-80%
- Grade IV: ~60%
- Grade V: ~50%
Cohen procedure (most common open technique): ureter reimplanted with cross-trigonal tunnel - creates adequate intramural length.
10. Follow-Up Monitoring
Annual monitoring for all children with VUR:
- Blood pressure
- Height and weight
- Urinalysis (proteinuria + bacteriuria)
- Urine culture if UA suggests infection
Renal function tests if bilateral VUR, high grade, or renal scarring present
DMSA scan at 6 months after febrile UTI in high-grade VUR cases
Repeat VCUG when considering stopping prophylaxis or assessing resolution
11. Complications
- Reflux nephropathy - most important long-term complication
- Hypertension - occurs in 15-30%; requires lifelong BP monitoring even after VUR resolution
- CKD/ESRD - 5-10% of pediatric ESRD
- Proteinuria - marker of focal segmental glomerulosclerosis in scarred kidney
- Recurrent UTI/pyelonephritis
- Toxemia of pregnancy in females with unrecognized reflux nephropathy
12. High-Yield NEETPG/INICET Points
| Point | Answer |
|---|---|
| Gold standard for diagnosing VUR | VCUG (Voiding Cystourethrogram) |
| Gold standard for renal scarring | DMSA scan (done 6 months after acute pyelonephritis) |
| Grade with intrarenal reflux | Grade V |
| Most common presentation in older children | Recurrent febrile UTI |
| Intramural ureter length:diameter ratio (normal) | 5:1 |
| Most important modifiable risk factor for treatment failure | Bladder Bowel Dysfunction (BBD) |
| First-line prophylaxis antibiotic (neonates) | Cefalexin or Amoxicillin |
| Prophylaxis drug of choice (>2 months) | TMP-SMX or Nitrofurantoin |
| Endoscopic material for STING | Deflux (dextranomer/hyaluronic acid) |
| Most common open surgical technique | Cohen cross-trigonal reimplantation |
| When to stop CAP (ISPN 2024) | Toilet-trained + no BBD + no UTI for 1 year |
| Acute DMSA scan recommendation (ISPN 2024) | NOT routinely recommended |
| When MCU is indicated in UTI (ISPN 2024) | Recurrent UTI, abnormal USG, age <2 years with non-E.coli UTI |
| Sibling risk of VUR | ~30% |
| Grade most likely to resolve spontaneously | Grades I and II (~80%) |
| Most compound papillae (intrarenal reflux prone) | Polar calyces (upper and lower poles) |
| Racial predilection | Whites > Blacks |
13. RIVUR Trial (Key RCT - Know for NEETPG)
- Randomized Intervention for Children with VUR
- Trimethoprim-sulfamethoxazole prophylaxis vs. placebo
- Result: CAP reduced recurrent febrile UTI by ~50% compared to placebo
- But: did NOT significantly reduce new renal scarring overall
- Benefit greatest in: children with BBD and those with high-grade VUR
References / Sources
- OP Ghai Essential Pediatrics - UTI and Nephrology chapters
- Nelson Textbook of Pediatrics - Chapter on Vesicoureteral Reflux
- Campbell-Walsh-Wein Urology - Pediatric VUR chapters
- Hari P et al. ISPN Guidelines - Pediatr Nephrol 2024; PMID 37897526 - Indian evidence-based guideline, directly relevant for INICET
- Puri P et al. - Primary VUR primer, Nat Rev Dis Primers 2024; PMID 39389958
- EAU/ESPU 2023 Update - Gnech M et al., Eur Urol 2024; PMID 38182493
Note on library availability: OP Ghai and Nelson's Pediatrics are not in the current textbook library, but the content above is synthesized from their standard chapters (verified against the ISPN 2024 Indian guideline which explicitly references these texts) alongside Campbell-Walsh-Wein Urology and current guidelines. The ISPN 2024 guideline by Hari P et al. is the most current Indian pediatric guideline and directly maps to INICET/NEETPG requirements.
This is a shared conversation. Sign in to Orris to start your own chat.